ACRUX LIMITED — Capital/Financing Update 2013

Oct 23, 2013

ACRUX (ACR) - ASX ANNOUNCEMENT

24 OCTOBER 2013

AXIRON NET SALES, QUARTER TO 30 SEPTEMBER 2013

Acrux (ASX: ACR) today confirmed that Eli Lilly reported global Axiron net sales of US$40.6 million in its financial results for the quarter ended 30 September 2013. Net sales reported by Lilly for the previous quarter to 31 June 2013 were US$47 million.

Axiron net sales for the 2013 calendar year to date are shown in the following table:

table:
Q1 2013	Q2 2013	Q3 2013	Total to date
US$37.1m	US$47.1m	US$40.6m	US$124.8m

The market continues to slow and Axiron’s share has flattened at the same time that Eli Lilly has undertaken a sales force restructuring. Quarter 3 sales have improved Acrux’s position, with the average royalty percentage of net sales having increased. In addition to royalties, Acrux will receive a milestone payment of US$25 million in March 2014 as the worldwide net sales of Axiron in the 2013 calendar year have now exceeded US$100 million, unless there is a material event resulting in a product recall.

Contact

Ross Dobinson, Chairman: 03 9691 5920

About Acrux

www.acrux.com.au

• Acrux is an Australian drug delivery company, developing and commercialising a range of patient-preferred, patented pharmaceutical products for global markets, using its innovative technology to administer drugs through the skin.

• The Acrux technology, used in marketed products including AXIRON®, Evamist® and Recuvyra™, is based on a fast-drying, small volume, accurately dosed solution, containing penetration enhancers, that when applied topically, deposit drug through the skin for long acting delivery.

• Acrux has three products marketed by licensees in the USA, three products approved in Europe, and further products at earlier stages of development.

==> picture [123 x 66] intentionally omitted <==

==> picture [360 x 66] intentionally omitted <==

==> picture [106 x 66] intentionally omitted <==